Concepedia

Publication | Open Access

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

DOIFull Paper Access

363

Citations

22

References

2009

Year

Carola A.S. Arndt, Julie A. Stoner, Douglas S. Hawkins, David A. Rodeberg, Andrea Hayes‐Jordan, Charles N. Paidas, David M. Parham, Lisa A. Teot, Moody D. Wharam, John C. Breneman,
Journal of Clinical Oncology

Abstract

For intermediate-risk RMS, VAC/VTC does not significantly improve FFS compared with VAC.

References

YearCitations

Page 1